The global neurovascular embolization devices market is anticipated to grow at a considerable CAGR of 6.3% during the forecast period. Arteriovenous malformations are a developmental anomaly of the vascular system, consisting of tangles of poorly formed blood vessels in which the feeding arteries are directly connected to a venous drainage network without any interposed capillary system. AVMs can occur anywhere in the body, however, brain AVMs are of special concern because of the inherent high risk of bleeding of the abnormal blood vessels that cause neurological damage. According to the National Institutes of Health, approximately 41.0% to 79.0% present with intracranial hemorrhage. AVMs are the second most common cause of intracranial bleed after cerebral aneurysms, responsible for 10.0% of all cases of subarachnoid hemorrhage. The incidence in the US is 1.3 per 100,000 persons, although the actual prevalence rate is higher due to clinically silent disease, as only 12.0% of AVMs are estimated to become symptomatic. The mortality rate is 10.0%-15.0% of patients who have a hemorrhage, and morbidity varies from approximately 30.0%-50.0%. AVMs tend to be clinically asymptomatic in 15.0% of cases until the presenting event occurs.
Browse the full report description of “Neurovascular Embolization Devices Market Size, Share & Trends Analysis Report by Product (Embolic Coils and Flow Diversion Devices), and by End-Use (Hospitals and Specialty Clinics), Forecast Period (2023-2030)” at https://www.omrglobal.com/industry-reports/neurovascular-embolization-devices-market
Furthermore, the increasing number of partnerships and collaborations to develop a product to cater to the demand for neurovascular embolization devices is accelerating the market growth. For instance, in December 2021, Wallaby Medical, a medical device company focused on developing and commercializing medical device products for treating stroke partnered with Japan Lifeline Co., Ltd., a publicly-listed medical device manufacturer and distributor with 48 sales offices across Japan, to bring Wallaby's Japan PMDA approved Avenir® Coil System to the Japanese market. Avenir® is used in the intravascular embolization of intracranial aneurysms and other neurovascular malformations such as arteriovenous malformations and arteriovenous fistulas, as well as arterial and venous embolization of peripheral blood vessels.
Market Coverage
• The market number available for – 2022-2030
• Base year- 2022
• Forecast period- 2023-2030
• Segment Covered-
o By Product
o By End-Use
• Regions Covered-
o North America
o Europe
o Asia-Pacific
o Rest of the World
• Competitive Landscape- including B. Braun Melsungen AG, Cerenovus Inc., Medtronic plc, Stryker Corp., and others.
Key questions addressed by the report
• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?
Global Neurovascular Embolization Devices Market Report Segment
By Product
By End-Use
Global Neurovascular Embolization Devices Market Report Segment by Region
North America
• United States
• Canada
Europe
• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe
Asia-Pacific
• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific
Rest of the World
• Latin America
• Middle East & Africa
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/neurovascular-embolization-devices-market